A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope

被引:12
作者
Li, Dong [1 ]
Li, Jing [1 ]
Chu, Huanyu [1 ]
Wang, Zhuozhi [1 ]
机构
[1] WuXi Biol, Biol Discovery, 227 Meisheng Rd, Shanghai 200131, Peoples R China
关键词
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); CD152; antibody; cross-species binding; epitope mapping; N-glycosylation; ANTI-CTLA-4; ANTIBODIES; CANCER-IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; IMMUNE-CHECKPOINT; CTLA-4; CELLS; TREMELIMUMAB; SIMULATIONS; DURVALUMAB; DEPLETION;
D O I
10.1080/19420862.2020.1725365
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CD152) is a receptor on T cells that inhibits the cell's functions. Blocking CTLA-4 with an antibody has proven effective for the treatment of cancer patients. Anti-CTLA-4 antibodies currently approved for clinical use can bind to human CTLA-4, but do not cross-react to murine CTLA-4. Here, we report the generation and characterization of a functional humanized antibody, mAb146, against both human and murine CTLA-4. Alanine scanning of CTLA-4 using mammalian cell expression cassette identified the unique epitopes of this novel antibody. In addition to the amino acid residues interacting with ligands CD80 and CD86, an N-glycosylation site on N110, conserved in CTLA-4 of human, monkey, and mouse, was identified as the specific epitope that might contribute to the cross-species binding and function of this antibody. This finding may also contribute to the understanding of the glycosylation of CTLA-4 and its related biologic function. In addition to facilitating preclinical development of anti-CTLA-4 antibodies, mAb146 may be useful as a therapeutic agent.
引用
收藏
页数:12
相关论文
共 34 条
[1]   Tremelimumab [J].
不详 .
Drugs in R & D, 2010, 10 (2) :123-132
[2]   Ipilimumab [J].
不详 .
Drugs in R & D, 2010, 10 (2) :97-110
[3]   Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].
Antonia, Scott ;
Goldberg, Sarah B. ;
Balmanoukian, Ani ;
Chaft, Jamie E. ;
Sanborn, Rachel E. ;
Gupta, Ashok ;
Narwal, Rajesh ;
Steele, Keith ;
Gu, Yu ;
Karakunnel, Joyson J. ;
Rizvi, Naiyer A. .
LANCET ONCOLOGY, 2016, 17 (03) :299-308
[4]   Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma [J].
Bahig, Houda ;
Aubin, Francine ;
Stagg, John ;
Gologan, Olguta ;
Ballivy, Olivier ;
Bissada, Eric ;
Nguyen-Tan, Felix-Phuc ;
Soulieres, Denis ;
Guertin, Louis ;
Filion, Edith ;
Christopoulos, Apostolos ;
Lambert, Louise ;
Tehfe, Mustapha ;
Ayad, Tareck ;
Charpentier, Danielle ;
Jamal, Rahima ;
Wong, Philip .
BMC CANCER, 2019, 19 (1)
[5]   Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping [J].
Bongers, Jacob ;
Devincentis, John ;
Fu, Jinmei ;
Huang, Peiqing ;
Kirkley, David H. ;
Leister, Kirk ;
Liu, Peiran ;
Ludwig, Richard ;
Rumney, Kathleen ;
Tao, Li ;
Wu, Wei ;
Russell, Reb J. .
JOURNAL OF CHROMATOGRAPHY A, 2011, 1218 (45) :8140-8149
[6]   CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation [J].
Chikuma, Shunsuke .
EMERGING CONCEPTS TARGETING IMMUNE CHECKPOINTS IN CANCER AND AUTOIMMUNITY, 2017, 410 :99-126
[7]   doGlycans-Tools for Preparing Carbohydrate Structures for Atomistic Simulations of Glycoproteins, Glycolipids, and Carbohydrate Polymers for GROMACS [J].
Danne, Reinis ;
Poojari, Chetan ;
Martinez-Seara, Hector ;
Rissanen, Sami ;
Lolicato, Fabio ;
Rog, Tomasz ;
Vattulainen, Ilpo .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2017, 57 (10) :2401-2406
[8]   Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer [J].
Fiegle, E. ;
Doleschel, D. ;
Koletnik, S. ;
Rix, A. ;
Weiskirchen, R. ;
Borkham-Kamphorst, E. ;
Kiessling, F. ;
Lederle, W. .
NEOPLASIA, 2019, 21 (09) :932-944
[9]   MODELLER: Generation and refinement of homology-based protein structure models [J].
Fiser, A ;
Sali, A .
MACROMOLECULAR CRYSTALLOGRAPHY, PT D, 2003, 374 :461-491
[10]   Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer [J].
Fumet, Jean-David ;
Isambert, Nicolas ;
Hervieu, Alice ;
Zanetta, Sylvie ;
Guion, Jean-Florian ;
Hennequin, Audrey ;
Rederstorff, Emilie ;
Bertaut, Aurelie ;
Ghiringhelli, Francois .
ESMO OPEN, 2018, 3 (04)